The Latin America, Middle East and Africa C-Reactive Protein Testing Market should witness market growth of 4.7% CAGR during the forecast period (2023-2030).
The uterine lining tissue can grow outside the uterus due to a condition known as endometriosis. Typically, the disease affects a woman's ovaries, fallopian tubes, and pelvic lining tissue. Additionally, the disease may expand outside of the pelvic area. Women with endometriosis are more sensitive to C-reactive protein than those without. Therefore, the test is widely used to identify the disease in patients. Retrograde menstruation, peritoneal cell transformation, embryonic cell transformation, implantation of surgical scars, transport of endometrial cells, and immune system abnormalities are the leading causes of endometriosis. The demand is anticipated to increase due to the disease's rising prevalence in women.
In patients with atherosclerosis, congestive heart failure, myocarditis, atrial fibrillation, and aortic valve disease, CRP levels have been associated with prognosis. Also, it worsens with disorders, including meningitis, cholecystitis, pancreatitis, and appendicitis. CRP levels and people at risk for any chronic inflammatory disease are identified utilizing high-sensitivity testing. Since CRP has been included in standard clinical practice, its demand is anticipated to increase, and the market will develop over the projection period. CRP has numerous uses in developing effective and secure anti-inflammatory drugs in both in vitro and in vivo research.
According to data from the International Agency for Research on Cancer's (IARC) GLOBOCAN 2020 database, the estimated results of the various cancer types available from 47 countries in WHO's African Region (AFRO) showed that 1109209 new cancer cases and 711429 cancer deaths were reported in AFRO countries. Throughout the forecast period, rising cancer rates in this region's developing countries and increased public awareness of diagnostics are anticipated to drive growth of the market.
The Brazil market dominated the LAMEA C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $62.3 million by 2030. The Argentina market is poised to grow at a CAGR of 5.2% during (2023-2030). Additionally, The UAE market would register a CAGR of 4.4% during (2023-2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
The uterine lining tissue can grow outside the uterus due to a condition known as endometriosis. Typically, the disease affects a woman's ovaries, fallopian tubes, and pelvic lining tissue. Additionally, the disease may expand outside of the pelvic area. Women with endometriosis are more sensitive to C-reactive protein than those without. Therefore, the test is widely used to identify the disease in patients. Retrograde menstruation, peritoneal cell transformation, embryonic cell transformation, implantation of surgical scars, transport of endometrial cells, and immune system abnormalities are the leading causes of endometriosis. The demand is anticipated to increase due to the disease's rising prevalence in women.
In patients with atherosclerosis, congestive heart failure, myocarditis, atrial fibrillation, and aortic valve disease, CRP levels have been associated with prognosis. Also, it worsens with disorders, including meningitis, cholecystitis, pancreatitis, and appendicitis. CRP levels and people at risk for any chronic inflammatory disease are identified utilizing high-sensitivity testing. Since CRP has been included in standard clinical practice, its demand is anticipated to increase, and the market will develop over the projection period. CRP has numerous uses in developing effective and secure anti-inflammatory drugs in both in vitro and in vivo research.
According to data from the International Agency for Research on Cancer's (IARC) GLOBOCAN 2020 database, the estimated results of the various cancer types available from 47 countries in WHO's African Region (AFRO) showed that 1109209 new cancer cases and 711429 cancer deaths were reported in AFRO countries. Throughout the forecast period, rising cancer rates in this region's developing countries and increased public awareness of diagnostics are anticipated to drive growth of the market.
The Brazil market dominated the LAMEA C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $62.3 million by 2030. The Argentina market is poised to grow at a CAGR of 5.2% during (2023-2030). Additionally, The UAE market would register a CAGR of 4.4% during (2023-2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
Scope of the Study
By Application
- Cardiovascular Disease
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
- Diabetes
- Others
By Assay Type
- Immunoturbidimetric Assays
- Enzyme-linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Others
By End-user
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Randox Laboratories Limited
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Horiba, Ltd.
- Merck KGaA
- Zoetis, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA C-reactive Protein Testing Market by Application
Chapter 5. LAMEA C-reactive Protein Testing Market by Assay Type
Chapter 6. LAMEA C-reactive Protein Testing Market by End User
Chapter 7. LAMEA C-reactive Protein Testing Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Randox Laboratories Limited
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Horiba, Ltd.
- Merck KGaA
- Zoetis, Inc.
Methodology
LOADING...
